XML 15 R6.htm IDEA: XBRL DOCUMENT v3.7.0.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
 3 Months Ended
Mar. 31, 2017
Mar. 31, 2016
CASH FLOWS FROM OPERATING ACTIVITIES    
Net (loss) attributable to Immudyne, Inc. $ (1,044,805) $ (62,049)
Net (loss) attributable to noncontrolling interests (27,730) (46,110)
Net (loss) (1,072,535) (108,159)
Adjustments to reconcile net (loss) to net cash (used) by operating activities    
Change in fair value of derivative liability 48,192
Bad debt recovery (38,027)
Amortization of debt discount 81,558
Loss on settlement of notes payable 553,222
Stock compensation expense 190,188 38,867
Changes in Assets and Liabilities    
Trade accounts receivable (72,938) (144,902)
Other receivables 2,250
Inventory 23,332 (77,443)
Accounts payable and accrued expenses (188,498) 169,482
Net cash (used) by operating activities (473,256) (122,155)
CASH FLOWS FROM FINANCING ACTIVITIES    
Investment in subsidiary by noncontrolling interest, net 43,378 92,793
Proceeds from notes payable 235,000
Repayment of convertible note payable (100,000)
Repayment of notes payable (151,420)
Sale of common stock and warrants 647,944
Purchase of treasury stock (3,151)
Net cash provided by financing activities 671,751 92,793
Net increase (decrease) in cash 198,495 (29,362)
Cash at beginning of the period 182,561 232,984
Cash at end of the period 381,056 203,622
Supplemental Disclosure of Cash Flow Information    
Cash paid during the period for interest 3,612 3,063
Issuance of company stock for notes and other payables 192,192
Conversion of equity invested in subsidiary to common stock and warrants 272,203
Reclassification of options, warrants and other contracts to derivative liabilities upon issuance $ 1,569,444